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Abstract
Ultrasound imaging has long demonstrated utility in the study and measurement of anatomic
features and noninvasive observation of blood flow. Within the last decade, advances in molecular
biology and contrast agents have allowed researchers to use ultrasound to detect changes in the
expression of molecular markers on the vascular endothelium and other intravascular targets. This
new technology, referred to as ultrasonic molecular imaging, is still in its infancy. However, in
preclinical studies, ultrasonic molecular imaging has shown promise in assessing angiogenesis,
inflammation, and thrombus. In this review, we discuss recent advances in microbubble-type
contrast agent development, ultrasound technology, and signal processing strategies that have the
potential to substantially improve the capabilities and utility of ultrasonic molecular imaging.
Traditional non–contrast-enhanced ultrasound imaging uses a transducer to produce pulses
of sound that propagate into tissue. These sound pulses are scattered from interfaces
between tissue components of different density and compressibility. Scattered ultrasound
reflections are detected and processed to form an image based on the intensity of scattered
echoes and the time delay, which corresponds to the depth from which echoes have returned.
As such, standard ultrasound imaging is well suited for assessment of anatomic features and
measurement of blood flow in large vessels; however, there is no mechanism by which non–
contrast-enhanced ultrasound can detect changes in physiology on a molecular level.
Contrast Agents
The fundamental enabling technology for ultrasonic molecular imaging is the contrast agent.
Contrast agents for ultrasound imaging include microbubbles,1–6 echogenic liposomes,7–9
perfluorocarbon droplets,10–12 and other materials such as gold particles,13 which have a
density and compressibility substantially different from that of blood and tissue. Highly
compressible objects provide an additional advantage in that they can resonate in a sound
field, producing a nonlinear acoustic response that enables detection strategies to segment
the echoes from the contrast agent from those of tissue.14–16 The supremely compressible
gas core of microbubble contrast agents (MCAs) makes them uniquely echogenic, so even
individual contrast agents can be detected with an ultrasound system.17 It is for this reason
that encapsulated microbubbles are the most prevalent form of contrast agent, and they are
currently the only type of ultrasound contrast agent approved for clinical use in the United
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States and Europe. Owing to the widespread research on and implementation of MCAs, the
technology discussed in this review pertains primarily to this type of contrast agent.
MCAs typically consist of a high-molecular-weight gas core stabilized with a lipid, protein,
sugar, or polymer.18,19 Early-generation MCAs contained nitrogen or air; however,
perfluorocarbons and sulfur hexafluoride are now preferred owing to their low solubility in
blood and poor diffusivity through the encapsulating shell, which extends microbubble
circulation time in vivo.19,20
Although nontargeted contrast agents are used clinically for assessing blood perfusion,
particularly in cardiology, molecularly targeted agents have still not received clinical
approval. Molecularly targeted contrast agents have a formulation similar to that of
nontargeted agents, except that they incorporate an adhesion mechanism in their shell so that
they can bind to cells expressing molecular signatures of pathology in vivo. Commonly used
adhesion ligands include peptides,21,22 antibodies,23,24 and disintegrins25,26 but may also
include peptidomimetics or other adhesion ligands that can be conjugated directly to the
contrast agent shell.27,28
Ultrasound Molecular Imaging
Molecular imaging is commonly associated with modalities such as positron emission
tomography (PET), single-photon emission computed tomography (SPECT), and optical
imaging; ultrasound, however, has several advantages over these and other imaging
modalities. Ultrasound systems are low cost, portable (and becoming even more so with
shrinking electronic components), and safe for both the user and the patient over repeated
use because of the lack of ionizing radiation. Additionally, ultrasound is a high frame rate,
real-time imaging modality, and has a better depth of penetration than optical imaging.
Finally, ultrasound has the unique ability to disrupt (clear) contrast agents,29,30 to
manipulate their distribution through radiation force,31 and to combine therapy with
imaging, allowing true implementation of “theranostics.”27,32–35
Molecular imaging with ultrasound is typically performed as follows: an ultrasound
transducer is fixed in position over the region of interest with a mechanical arm to avoid
motion artifacts from operator movement. A targeted contrast agent is administered into the
peripheral vasculature, often through a tail vein during serial imaging studies in rodents.
Prior to imaging, a waiting period of approximately 4 to 30 minutes is required, depending
on contrast agent circulation characteristics.36 During this period, there is a first phase when
the targeted contrast agents accumulate in the microvasculature, followed by a second phase
when freely circulating agents are cleared from the animal’s system. After free agent
clearance, imaging is performed to detect molecularly targeted contrast agents retained in
regions of pathologic tissue. When possible, a first acquisition of several imaging frames is
followed by a destruction pulse, which clears all contrast within the field of view. A second
set of imaging frames can then be gathered as a no-contrast baseline to quantify image
intensity increase owing to molecularly targeted agents.
Challenges in Molecular Imaging with Ultrasound
Although ultrasonic molecular imaging has made significant progress over the last decade,
this technology still faces several challenges before it can rise to its full diagnostic potential.
It is the ideal goal of this technology to determine if a molecular target is present and, if so,
to what degree. This requires that the contrast agents specifically adhere to their molecular
target and bind in quantities great enough to overwhelm the signal contributions from
nonspecific retention. Additionally, the ultrasound system should have sufficient sensitivity
to detect the targeted agents present at the site of pathology and be able to assess the
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pathology in its entirety. In this review, we hypothesize that several limitations have slowed
the progression of ultrasonic molecular imaging; however, recent advances in contrast agent
development, ultrasound technology, and detection strategies demonstrate the potential to
substantially improve the capabilities and utility of ultrasonic molecular imaging. We review
these challenges and recent advances in the following sections.
Low Numbers of Retained Contrast Agents
Given that the magnitude of the detected ultrasound signal is a function of the quantity of
contrast agents retained at the site of target endothelium, it is intuitive that the retention of
targeted contrast agents at a site of diseased tissue should be maximized, whereas
nonspecific contrast retention should also be minimized. For molecular imaging studies in
small animals, the injected concentration of microbubbles is typically on the order of 107 to
108 bubbles/kg. Prior studies assessing the adhesion of targeted microbubbles have observed
only small amounts of targeted contrast retained in vivo, on the order of several bubbles per
cubic millimeter.25,37 Correspondingly, video intensity from targeted agents in vivo is
typically only several fold higher than background.23,26,38,39
High Background from Freely Circulating Agents
The high background signal from freely circulating contrast agents further complicates the
ability to detect small numbers of adherent targeted contrast agents. With the large total
injected dose of contrast and the very small percentage of the total dose that is retained in
target microvasculature, the scattered ultrasound signal from nontargeted contrast
overwhelms signal from targeted contrast.40–42 As previously mentioned, the current
technique for molecular imaging deals with this limitation through a waiting period (Figure
1). After injection of the bolus of targeted contrast agent, a waiting period between several
and tens of minutes is implemented prior to imaging. During this time, freely circulating
microbubbles are slowly cleared from the circulation by the reticuloen-dothelial system,
nonspecific retention, and bubble deterioration.43–45 Although this waiting technique is not
a significant challenge in a molecular imaging procedure, it is possible that a percentage of
microbubbles retained at the target site both detach and degrade over this time period,
reducing the method’s sensitivity.
Limited Field of View
One limitation of ultrasound imaging, in general, compared to modalities such as computed
tomography (CT), magnetic resonance imaging (MRI), PET, and SPECT, is a smaller field
of view. Until fairly recently, ultrasound imaging was largely a two-dimensional modality,
depicting only a single image slice through tissue. In diagnostic imaging, the real-time
imaging capability compensates for this as it allows a sonographer to scan through the tissue
of interest to view or measure target features. In ultrasonic molecular imaging, however,
most current protocols involve maintaining the transducer fixed in a clamp to observe the
same slice of tissue. This is usually required because quantifiable measurement of signal
from contrast involves a background subtraction after a destructive pulse, which creates
artifacts in the presence of tissue or transducer motion. Recent advances in transducer
technology have led to the implementation of matrix array transducers, allowing real-time
three-dimensional ultrasound imaging (also called four-dimensional, considering the time
dimension). Three-dimensional ultrasound is still relatively new to the clinic and is used
primarily in obstetrics and cardiology. However, due to the complicated pulse sequences
required to differentiate MCAs from surrounding tissue, three-dimensional contrast imaging
has been challenging to implement on matrix array probes. Although some ultrasound
system manufacturers currently have real-time three-dimensional contrast imaging
capability, the performance of contrast imaging modes on matrix array transducers still falls
short of the resolution and contrast detection capability available on transducers for two-
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dimensional imaging. Hence, to date, ultrasonic molecular imaging has been largely limited
to a single slice of tissue.
Quantitative Ability
An ideal goal of any imaging modality is to achieve a quantitative measurement. Although
non–contrast-enhanced ultrasound can reliably allow anatomic measurements, contrast-
enhanced ultrasound imaging is still largely qualitative and based on relative video intensity
changes. The precise relationship between the number and distribution of retained targeted
MCAs in tissue and the resulting acoustic response is still unknown. The scattered signal
from a targeted MCA is a complex function of the microbubble size,46,47 the damping
effects of the surroundings,48–50 and interactions with other local MCAs.51 Additionally,
the ultrasound response is attenuated by tissue, both as a function of depth and as a function
of tissue type. Until an imaging system is able to estimate the number of microbubbles
retained in tissue, it will be challenging to perform accurate quantitative measurements of
molecular marker expression with ultrasonic imaging.
Possible Immune Responses
For contrast agents used in ultrasound molecular imaging studies, there is the possibility of
an immunogenic response triggered by contrast agent components or the various targeting
ligand compositions on their surfaces. To date, clinical studies have not been reported with
molecularly targeted contrast agents, and preclinical and clinical imaging studies using
nontargeted microbubbles have been associated with hypersensitivity reactions only in rare
cases.52–54 However, in preclinical studies, researchers have observed enhanced
complement activation, reduced circulation time, and nonspecific adhesion associated with
MCAs as a function of their shell components.42,55,56
Advances in Molecular Imaging with Ultrasound
Although the aforementioned challenges provide some limitations to molecular imaging
with ultrasound, recent advances in technology have demonstrated that many of these
limitations can be ameliorated. In the next sections, we review several technologies and
approaches that are notable improvements in ultrasonic molecular imaging.
Contrast Agents
New and Multiligand Approaches—To improve contrast agent retention at the desired
target site, many groups are pursuing mechanisms to improve agent-endothelium adhesion
with new approaches. Several groups have demonstrated enhanced microbubbles targeting
through the use of multiple adhesion ligands (Figure 2A).57–59 To improve targeting of
microbubbles to inflamed tissues, both Weller and colleagues and Ferrante and colleagues
have modeled their targeted contrast agents after biologic leukocytes by incorporating
ligands targeted to both selectins and immunoglobulin adhesion molecules.57,58
Proinflammatory selectins (such as E and P selectin) are naturally expressed by surface
endothelial cells, thus promoting the rolling action of leukocytes. Immunoglobulin adhesion
molecules (such as intercellular adhesion molecule 1 [ICAM-1] and vascular cell adhesion
molecule 1 [VCAM-1]) promote the firm binding of leukocytes and the transmigration of
leukocytes into tissue in regions where these proteins are expressed. The incorporation of
both types of binding mechanisms in microbubble shells resulted in a significantly improved
targeting efficiencies of between 50 and 300% when compared to bubbles bearing only a
single targeting ligand.58 The mechanism for this improvement is hypothesized to be due to
the rolling action of contrast agents along the blood vessel wall facilitated by selectin
adhesion, which improves the likelihood of a longer-lasting integrin bond forming at the
target site.
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Another method to improve the likelihood of micro-bubble targeting has been demonstrated
by altering ligand architecture. Klibanov and colleagues demonstrated that polymeric forms
of sialyl Lewisx (Figure 2B) were more efficient at binding to models of inflammation both
in vitro and in vivo than antibody-mediated targeting.60 Although the two demonstrated
comparable targeting efficiencies at a slow flow rate (0.68 dyne/cm2 shear stress), the
efficiency of the antibody-mediated targeted contrast agents was reduced by more than 20-
fold at a fast flow rate (4.45 dyne/cm2 shear stress).60
Bubble Size Optimization—Size is one of the most important parameters in micro-
bubble acoustic response. Microbubble diameter is directly related to scattering cross
section,61 resonant frequency,62 destruction threshold,63 nonlinear oscillation,64 and
susceptibility to radiation force.65 Additionally, in the size range typically used for contrast
imaging (≈1–7 μm), the changes in resonant frequency as a function of diameter are
substantial.66 This means that for a polydisperse contrast agent population, it is unlikely that
all of the contrast agents will be in the diameter range optimized for imaging, radiation
force–mediated displacement, or clearance (destruction). Most MCAs are produced with
technologies that result in a size distribution with a large variance. With traditional contrast-
enhanced ultrasound imaging, there has been little need to consider contrast agent size
distribution. This is largely due to the fact that millions to billions of microbubbles can be
injected into a patient during an imaging examination.67 However, in molecular imaging,
where low contrast retention is already an issue, it is important to be maximally sensitive to
the entire contrast agent population. Talu and colleagues demonstrated that contrast agents
with a uniform size distribution produce a substantially more correlated acoustic response
than polydisperse populations and that a monodisperse population of MCAs can be more
easily tailored to match the imaging system’s frequency for optimal acoustic response.68 It
is hypothesized that microbubble monodispersity will likely be required to elucidate
quantifiable information from molecular imaging studies.69
Given that the diameter of microbubbles plays a direct role in echogenicity, several
researchers have examined the potential of improving ultrasound contrast sensitivity by
altering microbubble size distribution. In vitro studies of monodisperse microbubbles by
Kaya and colleagues demonstrated that a severalfold increase in echogencity could be
achieved by increasing microbubble diameter (Figure 3).47 Sirsi and colleagues used high-
frequency (40 MHz) imaging for studying perfusion in the mouse kidney and observed that
contrast intensity doubled for microbubbles of 4 to 5 μm in mean diameter compared to
bubbles with a 1 to 2 μm mean diameter.70 Contrast enhancement was improved even more
with 6 to 8 μm MCAs. The advantages of size-sorted MCAs in molecular imaging
applications were demonstrated by Streeter and colleagues in a rat tumor model using
nonlinear imaging at 8 MHz, where sorted 3 μm MCAs were observed to provide a 20-fold
improvement in sensitivity over polydisperse 1 μm MCAs (Figure 4).36 Neither Sirsi and
colleagues nor Streeter and colleagues observed limitations in microbubble circulation
owing to the size of the larger microbubbles; in contrast, signals from larger microbubbles
were observed to persist for a period of time several times greater than smaller
microbubbles. Although these results suggest that larger bubbles are better suited for
molecular imaging with ultrasound, additional studies to examine the trade-off between
adhesion efficiency versus signal intensity as a function of microbubble size have yet to be
performed.
Creating bubbles of uniform sizes and varying mean diameters can be achieved with
technology such as microfluidics,71–74 electrohydrodynamic atomization,75 differential
centrifugation,76 and other formulation techniques.69,77 Although these new formulation
techniques have been successful in providing monodisperse or size-selected microbubbles in
small amounts, in general, their complexity and low production rate are still limiting factors
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in the ability to produce sufficient size-optimized bubbles in commercially available
quantity.
Bubble and Shell Architecture—Modeling targeted microbubbles after their naturally
occurring analogues, leukocytes, is an intuitive strategy for optimizing their targeting
efficiency. One of the distinct differences between these two targeting agents—bubbles and
leukocytes—is their structural morphology during targeting events. Leukocytes are known
to become more deformable on chemical activation as a result of cytoskeletal
rearrangements. This increased deformability increases their contact area with the
endothelial surface, which also simultaneously increases the number of potential bonds with
the endothelium and decreases the load per bond formed. It has been hypothesized that the
relative structural rigidity of bubbles compared to leukocytes is partially responsible for
their poor retention rates at their desired target sites as fewer bonds formed implies higher
stresses applied to each of them after targeting and thus a greater likelihood of detachment.
78 Rychak and colleagues demonstrated the means to create bubbles with excess deformable
lipid in their shells (Figure 2C), resulting in a greater deformability.78 These deformable, or
“wrinkly,” bubbles were more effective in molecular imaging studies targeted to the
inflammatory protein P-selectin, both in vitro and in vivo, at forming stable bonds at their
target sites. Relative to spherical bubbles, bubbles with excess surface lipid showed
significantly better sustained targeting efficiency in vitro at wall shear stresses between 0.34
and 1.3 dyne/cm2, as well as at targeting site densities between 7 and 109 sites/μm2. The in
vivo retention rate of wrinkly bubbles was twice that of spherical bubbles, as determined by
intravital microscopy in a cremaster muscle of a mouse model of inflammation (Figure 5).
Reduction in Immunogenicity—It has been possible to significantly reduce
complement activation from targeted microbubbles by implementing buried-ligand
architectures (Figure 2D).55,56 With this technique, both the polyethylene glycol brush
chains and targeting ligand chains are conjugated to the lipid shell of the contrast agents.
The brush chains are longer than the ligand chains and thus veil the ligands from the various
blood components that could otherwise trigger an immunogenic reaction. Borden and
colleagues demonstrated that buried-ligand architectures were able to help isolate the
targeting ligands from their surroundings until the bubbles were intentionally activated with
an acoustic radiation force pulse, which transiently revealed the buried ligand to the target
site.55 The strategy showed a significant improvement over conventional exposed-ligand
micro-bubbles in avoiding immunogenic responses (Figure 6).
Imaging and Detection Technology
Real-Time Molecular Imaging—To overcome the challenge of detecting small numbers
of retained targeted contrast agents with a high background of freely circulating agents
without a waiting period, several groups have been developing real-time molecular imaging
approaches. Zhao and colleagues proposed two methods to help accomplish this goal of real-
time imaging of bound contrast agents.40 The first “image-push-image” method improves
imaging sensitivity by increasing the number of adherent agents via a radiation force push of
contrast agents toward the distal wall of the blood vessel. The prepush image is subtracted
from the postpush image to yield the signal from adherent agents. The second real-time
ultrasound molecular imaging strategy proposed in that article was to implement a “slow-
time” filtering approach in which successive frames are low-pass filtered such that rapidly
changing signals (namely those from nonstationary bubbles) are removed from the image
data (Figure 7). Because both adherent bubbles and tissue are equivalently stationary, this
second strategy necessitates a contrast-specific imaging technique with a high degree of
tissue suppression. Real-time molecular imaging methods have been demonstrated in vitro
with several different contrast-specific methods, including subharmonic imaging79 and
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pulse inversion.80 Zheng and colleagues and Gessner and colleagues recently demonstrated
application of dual-frequency transducers and pulse sequences designed for production of
radiation force and real-time targeted MCA detection without a waiting period.81,82
Low Mechanical Index Imaging—MCAs are destroyed by ultrasound energy, primarily
as a function of microbubble diameter, acoustic frequency, and acoustic amplitude.63 Low–
mechanical index imaging strategies use low amplitudes and higher frequencies to minimize
MCA destruction. These imaging strategies are advantageous because of their ability to
image adherent targeted contrast agents over time after a single administration. Additionally,
nondestructive imaging will likely be required to facilitate three-dimensional and
quantitative molecular imaging as destructive imaging techniques require that all of the
signal from targeted contrast agents must be acquired during the first imaging pulse to which
the contrast agents are exposed, which is practically challenging.
Many commercial imaging systems now include low–mechanical index contrast imaging
modes, such as (but not limited to) Cadence contrast pulse sequence (CPS, Siemens,
Mountain View, CA)26,83 and contrast harmonic imaging (CHI, Philips, Bothell, WA).
84,85 Recently, Needles and colleagues demonstrated the application of low–mechanical
index contrast imaging modes at frequencies greater than 15 MHz on a high-frequency array
system.86
Volumetric Imaging—Recent studies by Gessner and colleagues82 and Streeter and
colleagues (Figure 8; unpublished data, 2009) demonstrated the utility of three-dimensional
molecular imaging. By acquiring multiple two-dimensional images via a motorized stage
and reconstructing the data offline, heterogeneities within pathologic tissue volumes are
observed that would be impossible to assess with traditional single-slice molecular imaging.
Three-dimensional contrast imaging capabilities are currently in development,85,87 and
continued improvements in low–mechanical index, high–resolution, three-dimensional
imaging will soon allow for the full volumetric characterization of tissue pathologies. This
will ensure consistent data collection in longitudinal studies by avoiding the possibility of
undersampling heterogeneous tissues.
Improvements in Microbubble Delivery
Radiation Force–Enhanced Targeting—For highly compressible objects such as
MCAs, acoustic radiation force can be of a substantial magnitude even at low acoustic
pressures.65 A transducer directing energy perpendicular to flow in a vessel can displace
moving MCAs to the wall of the vessel opposite the sound source and greatly enhance
microbubble–endothelium interactions. Dayton and colleagues previously proposed this
mechanism for enhanced targeting of microbubbles because radiation force both decreases
ligand-receptor distances and reduces the flow velocity of microbubbles in a vessel.88 The
capability of radiation force to enhance targeted MCA retention was observed in vivo with
intravital microscopy by Rychak and colleagues89 and acoustically by Gessner and
colleagues.82 In a rat model of angiogenesis, application of radiation force prior to imaging
demonstrated a sevenfold increase in image intensity compared to the control case (Figure
9).82 This application of radiation force to enhance retention of targeted microbubbles is
particularly attractive for applications that use microbubbles as therapeutic vehicles.
Submicron Contrast Agents—A significant limitation of traditional MCAs is that their
several-micron diameter range retains these agents to the vascular space. Several attempts
have been made to overcome this limitation. Submicron (< 1 μm) microbubbles have been
formulated with polymer shells. Although the extravasation potential of these agents has not
been confirmed, Patel and colleagues demonstrated their acoustic activity,90,91 and Wisner
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and colleagues used these sub-micron agents for lymphographic ultrasound imaging.92 Gao
demonstrated that stabilized liquid perfluorocarbon nanodroplets can be formulated with a
diameter range small enough to extravasate but then can be vaporized into microgas bubbles
by a combination of body temperature and ultrasound energy.93 Once vaporized, these
vehicles are detectable with ultrasound similar to MCAs. Thus, it is likely that contrast
agents can be prepared to exit the vascular space, particularly in regions of leaky tumor
vasculature, which is not currently possible with MCAs.
Conclusion
Molecular imaging with ultrasound is an exciting field because it adds a new dimension of
diagnostic capability to this already ubiquitous modality. It is certain that the future role of
ultrasound in medicine will continue to increase owing to its safety and convenience.
Already some manufacturers are producing diagnostic systems no larger than a cellular
phone that are intended to be as widely available as stethoscopes. With advancing
understanding in molecular changes involved in disease progression, molecular imaging will
enable detection of pathology and observation of response to treatment before phenotypic
changes occur.
As illustrated in this review, technology already exists to increase the sensitivity of
ultrasound to contrast agents severalfold through tailoring contrast agent size distribution.
Improving the monodispersity of the contrast agent population will remove a substantial
variable limiting the ability to perform quantifiable contrast measurements. Modifying shell
structure and ligand architecture can provide targeted contrast agents with better retention
characteristics and reduced immunogenicity. Transducers and signal processing are being
developed to detect targeted contrast agents nondestructively, with high contrast to tissue
ratios, and in real time despite background signal from freely circulating contrast. The
application of radiation force has been shown to increase the amount of targeted contrast
agents retained at a target site in vivo, which is important not only for molecular imaging but
also for targeted drug delivery through acoustically active carrier vehicles. Finally, the
development of phase change and submicron contrast agents will enable ultrasound contrast
to reach beyond the limits of the endothelium.
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A cartoon graph illustrating how freely circulating and targeted microbubbles contribute to
the overall concentration of contrast within an in vivo environment. Adapted from
Christiansen JP and Lindner JR.41 MCA = microbubble contrast agent.
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A schematic showing different microbubble shell and targeting ligand architectures. A,
Multiple-targeting ligands, such as selectin and immunoglobin adhesion molecules, improve
the likelihood of targeting by facilitating a rolling action along vessel walls. B, Polymeric
forms of targeting ligands promote the likelihood of sustained adhesion. C, Excess lipid in
shell (“wrinkly bubbles”) improves sustained microbubble retention. D, Buried-ligand
architecture (“stealthy bubbles”) reduces both nonspecific binding and immunogenic
reactions by veiling targeting ligands from complement proteins until transiently revealed at
the desired target site.
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The relationships between excitation frequency, micro-bubble radius, and resulting echo
amplitude. Five-cycle excitation pulses pressure-matched to 100 kPa. Echo amplitudes for
each microbubble diameter were maximized near their resonant frequencies, with the
greatest achievable response increasing with increasing microbubble size. Adapted from
Kaya M et al.47
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The relative image intensity improvement between size-isolated large targeted and control
microbubbles (left) and targeted and control microbubbles with smaller unsorted
polydisperse distributions (right). Injected concentrations were matched to 3 × 107 bubbles/
mL and imaged after freely circulating bubbles had cleared. Reproduced from Streeter JE et
al.36
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Improvement in targeting retention efficiency of wrinkled (WNKL) microbubbles (MB)
compared to traditional spherical (SPHR) microbubbles. Both populations were targeted to
P-selectin Rb40.34 with rat monoclonal antibodies. Data acquired using intravital
microscopy in 10 different venule locations within both wild-type (WT) and P-selectin-
deficient control (P−/−) mice, with n = 4 and n = 3, respectively. Adapted from Rychak JJ et
al.78 WSS = wall shear stress.
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Enzyme-linked immunosorbent assay analysis illustrating reduced immunogenic response
associated with a buried-ligand architecture microbubble compared to a conventional
exposed-ligand targeted bubble. Biotin ligands were used in this study. Anaphalatoxin C3a
concentration measured after 30-minute in vitro incubation in human serum. “Blank” was
PBS only and “control” was a distribution of bubbles bearing no ligand. Adapted from
Borden MA et al.56
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In vitro images in a flow phantom demonstrating a method to delineate stationary from
freely circulating bubbles in real time. Both freely circulating bubbles and stationary bubbles
can be seen in A, although in B the signal intensity from freely circulating bubbles is
suppressed with a slow-time interframe filter. Bubbles were forced to the distal wall of the
vessel with radiation force pulse prior to image collection. The stationary bubble signal is
indicated by the white arrow in both A and B. Field of view is 4.5 × 18 mm. Adapted from
Patil AV et al.80
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Three-dimensional molecular imaging of angiogenesis in a rat fibrosarcoma model. The data
illustrate the heterogeneity of microbubble targeting throughout the tumor volume (Streeter
and colleagues, unpublished data, 2009). A, Three-dimensional rendered isosurface
produced from B-mode data with manually defined regions of interest around the perimeter.
B, Corresponding overlaid two-dimensional frames, as seen on an imaging system, prior to
three-dimensional reconstruction. Grayscale anatomic images were collected with B-mode,
whereas green overlaid contrast-only images were collected with Siemens contrast pulse
sequence (Mountain View, CA).
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Images and data illustrating the improvement in targeting efficiency facilitated by the
application of radiation force (RF) in an angiogenic rat tumor model. A and B are three-
dimensional reconstructions of two-dimensional imaging planes acquired after freely
flowing bubbles cleared from the system. A, RF not administered. B, RF pulses administered
for 15 seconds after bolus injection of contrast. Scale bars are 1 cm. C, Plot comparing
targeted signal between acquisitions with RF application and without. A mean signal
increase of 13 dB was observed across all slices in response to RF. Adapted from Gessner R
et al.82
Gessner and Dayton Page 21
Mol Imaging. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
